Puma Biotechnology (PBYI)

• Market cap: $145M
• 1 day: -1.99%
• 5 days: -2.31%
• 1 month: -1.99%
• 3 months: 5.71%
• 6 months: -20.64%
• Year to date: -5.13%
• 1 year: -40.80%
• 5 years: -63.46%
• 10 years: -98.61%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Employees: 185

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

191% more call options, than puts

Call options by funds: $166K | Put options by funds: $57K

43% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 23

12% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 17

1% more funds holding

Funds holding: 99 [Q2] → 100 (+1) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

4.19% less ownership

Funds ownership: 64.92% [Q2] → 60.73% (-4.19%) [Q3]

26% less capital invested

Capital invested by funds: $102M [Q2] → $76M (-$26.1M) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $7 136% upside
• Avg. target: $7 136% upside
• High target: $7 136% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Edward White 28% 1-year accuracy 42 / 148 met price target

136% upside $7

Buy Reiterated

23 Dec 2024